Letermovir

• Letermovir (LMV) prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients with CMV seropositive donors Recruiting
  2024-516011-24-01 Phase II 1 country Grupo Espanol De Trasplante Hematopoyetico Y Terapia Celular
• Letermovir/valganciclovir combination versus valganciclovir monotherapy for treatment of cytomegalovirus (CMV) infections in kidney transpla… Recruiting
  2023-506216-40-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• " Prenatal treatment of congenital cytomegalovirus infection with letermovir randomized against valaciclovir (CYMEVAL III) Recruiting
  2024-512869-14-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Prospective study to evaluate the efficacy of letermovir prophylaxis for the prevention of CMV infection in lung transplant recipients compa… Ended
  2023-504384-16-00 Phase II 1 country Fundacion Para La Investigacion Biomedica De Cordoba
• Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study Ended
  2024-517354-98-00 Phase II 1 country University Medical Center Ljubljana
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA… Ended
  2023-503830-27-00 Phase II 3 countries Allogene Therapeutics Inc.
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 Phase II 2 countries Allogene Therapeutics Inc.

Showing 1–7 of 7 trials